Drugs / Maolactin
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT06444763 | Feb 2025 → Feb 2026 | arthropathy, myopathy | RDC Clinical Pty Ltd | Completed | No outcome recorded |
| Phase 3 | NCT06436781 | Sep 2024 → May 2025 | myofascial pain syndrome | RDC Clinical Pty Ltd | Completed | No outcome recorded |
| Phase 3 | NCT06104917 | Feb 2024 → Jul 2025 | bowel dysfunction | RDC Clinical Pty Ltd | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Maolactin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06436781 ↗ |
| Known as | MaolactinTM | “Effect of MaolactinTM Supplement on Gastrointestinal Tract (GIT) Health in Adult Subjects: a Double-blind Randomized Placebo-controlled Study” NCT06104917 ↗ |
| Modality | Protein / enzyme biologic | “250mg active proteins per capsule” NCT06104917 ↗ |